Babiak J, Rudel L L
Baillieres Clin Endocrinol Metab. 1987 Aug;1(3):515-50. doi: 10.1016/s0950-351x(87)80022-8.
The plasma lipoproteins are the primary means of transport of cholesterol among tissues. In particular, the apo B-containing lipoproteins (VLDL, IDL and LDL) are important for the delivery of cholesterol from the liver to peripheral tissues, while HDL appear to mediate the reverse process of movement of cholesterol from tissues back to the liver. Both of these transport processes are necessary for efficient whole body cholesterol homeostasis, because the liver is the major site of both the production and excretion of cholesterol. However, deviations from a proper balance of transport of cholesterol, either increases in LDL levels or decreases in HDL cholesterol flux, may result in accumulation of cholesterol in extrahepatic tissues. Increased risk of atherosclerosis and CHD may be associated with elevation in the number of LDL particles, increase or decrease in LDL particle size, or changes in the composition of plasma LDL. These modifications of plasma LDL may be brought about following perturbation of one of several aspects of LDL metabolism. These include decreased LDL receptor activity, increased VLDL production and cholesterol enrichment of the liver-derived VLDL. The events in the arterial wall that make some LDL particles apparently atherogenic are not well understood. In the case of nonhuman primates, large-size LDL are associated with an increased risk of CHD. One characteristic of these LDL is that their core lipids are rich in saturated cholesteryl esters and their transition temperatures are frequently above body temperature. The liquid crystalline cholesteryl ester cores of such LDL may modulate the conformation of apo B on the surface and thereby affect the interaction of these LDL with cellular receptors or connective tissue matrix proteoglycans. It is likely, though, that changes in LDL particle number, LDL particle size and LDL particle composition may each contribute to progression of atherosclerosis. The presumed metabolic events that make HDL protective against atherosclerosis have been termed reverse cholesterol transport, and suggest that small HDL that are deficient in free cholesterol acquire this lipid from cell membranes. The HDL cholesterol is esterified by LCAT in the circulation, forming large HDL that can then deliver the cholesteryl ester to the liver by both direct and indirect means. In most circumstances, it is assumed that an increase in plasma HDL cholesterol concentration reflects an increase in the rate at which HDL is removing cholesterol from tissues and, consequently, a decrease in atherosclerosis.(ABSTRACT TRUNCATED AT 400 WORDS)
血浆脂蛋白是胆固醇在组织间运输的主要方式。特别是,含载脂蛋白B的脂蛋白(极低密度脂蛋白、中间密度脂蛋白和低密度脂蛋白)对于将胆固醇从肝脏输送到外周组织很重要,而高密度脂蛋白似乎介导了胆固醇从组织回到肝脏的逆向运输过程。这两个运输过程对于有效的全身胆固醇稳态都是必需的,因为肝脏是胆固醇产生和排泄的主要部位。然而,胆固醇运输平衡的偏差,无论是低密度脂蛋白水平升高还是高密度脂蛋白胆固醇通量降低,都可能导致胆固醇在肝外组织中积累。动脉粥样硬化和冠心病风险的增加可能与低密度脂蛋白颗粒数量增加、低密度脂蛋白颗粒大小增加或减少,或血浆低密度脂蛋白组成的变化有关。血浆低密度脂蛋白的这些改变可能是在低密度脂蛋白代谢的几个方面之一受到干扰后发生的。这些包括低密度脂蛋白受体活性降低、极低密度脂蛋白产生增加以及肝脏来源的极低密度脂蛋白胆固醇富集。使一些低密度脂蛋白颗粒明显具有致动脉粥样硬化性的动脉壁内事件尚未完全了解。在非人类灵长类动物中,大尺寸低密度脂蛋白与冠心病风险增加有关。这些低密度脂蛋白的一个特征是它们的核心脂质富含饱和胆固醇酯,并且它们的转变温度经常高于体温。这种低密度脂蛋白的液晶胆固醇酯核心可能调节表面载脂蛋白B的构象,从而影响这些低密度脂蛋白与细胞受体或结缔组织基质蛋白聚糖的相互作用。不过,低密度脂蛋白颗粒数量、低密度脂蛋白颗粒大小和低密度脂蛋白颗粒组成的变化可能都有助于动脉粥样硬化的进展。推测的使高密度脂蛋白具有抗动脉粥样硬化作用的代谢事件被称为逆向胆固醇转运,这表明缺乏游离胆固醇的小高密度脂蛋白从细胞膜获取这种脂质。循环中的高密度脂蛋白胆固醇被卵磷脂胆固醇酰基转移酶酯化,形成大的高密度脂蛋白,然后可以通过直接和间接方式将胆固醇酯输送到肝脏。在大多数情况下,人们认为血浆高密度脂蛋白胆固醇浓度的增加反映了高密度脂蛋白从组织中清除胆固醇的速率增加,因此动脉粥样硬化程度降低。(摘要截选至400字)